Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth

Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" has been added to ResearchAndMarkets.com's offering.

The molecular diagnostics for infectious disease market is positioned for continued growth as technological innovation, emerging pathogens and changing global health priorities reshape clinical testing. The report examines an increasingly complex and segmented market, providing insight into the technologies, commercial opportunities and competitive developments influencing infectious disease diagnosis and treatment worldwide.

Multiplex assays are among the most significant forces transforming infectious disease testing. By enabling laboratories and healthcare providers to evaluate multiple pathogens in a single workflow, these assays are changing diagnostic strategies, treatment decisions and laboratory operations. The report assesses the growing impact of multiplex testing alongside advances in genomics, nucleic acid testing, immunoassays and rapid diagnostic platforms.

Market expansion is being supported by several interconnected trends:

The report analyzes how these factors are affecting market growth, product development, company valuations and investment priorities. Particular attention is given to the competitive relationship between nucleic acid testing and immunoassay technologies. Continued innovation in both areas is creating new opportunities for diagnostic companies while encouraging healthcare systems to adopt more accurate, scalable and efficient testing solutions.

As infectious disease diagnostics become more advanced, testing is expected to play a larger role in surveillance, antimicrobial stewardship, outbreak response and disease eradication initiatives. Genomics and related biotechnology advances are accelerating pathogen identification and supporting the development of assays designed for evolving clinical requirements. Rapid testing platforms are also expanding access to actionable results in hospitals, laboratories, physician offices and other care environments.

The research includes extensive market intelligence covering 15 countries and four regions, enabling organizations to evaluate geographic opportunities and understand differences in market conditions. Purchasers may also request a detailed breakout for any country worldwide, supporting market entry assessments, strategic planning and international business development.

To assist with pricing and reimbursement analysis, the report provides a comprehensive list of current United States Medicare Fee Payment Schedules. It also identifies frequently used and billed infectious disease tests, offering practical information for companies developing pricing strategies, forecasting revenue or evaluating reimbursement conditions.

The report is designed for diagnostic manufacturers, biotechnology companies, clinical laboratories, healthcare organizations, investors and other stakeholders seeking informed analysis of the infectious disease diagnostics market. Its findings can support product planning, competitive benchmarking, market forecasting, partnership development and investment decisions.

Purchasers receive access to additional assistance and specific supporting data without extra charges. Report data is also available in Excel format upon request, allowing teams to conduct customized analysis, integrate findings into internal models and efficiently share market intelligence across their organizations.

Key Topics Covered:

1 Market Guides

1.1 Situation Analysis

2 Introduction and Market Definition

2.1 Market Definition

2.1.1 Market Size

2.1.2 Currency

2.1.3 Years

2.2 Methodology

2.2.1 Methodology

2.2.2 Sources

2.2.3 Authors

2.3 Perspective: Healthcare Spending

2.3.1 Global Healthcare Spending

2.3.2 Spending on Healthcare and Pharmaceuticals

2.3.3 Spending on Diagnostics

2.3.4 Important Role of Insurance for Medical Services

2.4 The Nature of the IVD Product

2.4.1 Features Overview

2.4.2 The Misunderstood Feature

2.4.3 Regulation

2.4.4 The Newest Feature

2.4.5 The Oldest Feature

2.4.6 All About Scope

2.4.7 Why Turnaround is Becoming More Important

2.4.8 The Role of Trust

2.5 The IVD Product of the Future

3 Infectious Diseases - Guide to the Pathogens

3.1 Infectious Disease Pathogens - The Big Picture

3.1.1 Viruses

3.1.2 Bacteria

3.1.3 Fungi

3.1.4 Parasites

3.1.5 Prions

3.1.6 Virulence

3.1.7 Transmission

3.2 The Coronavirus

3.2.1 Severe acute respiratory syndrome (SARS)

3.2.2 Middle East respiratory syndrome (MERS)

3.2.3 COVID-19. The SARS CoV 2 Virus

3.2.3.1 Signs and symptoms

3.2.3.2 Transmission

3.2.3.3 Diagnosis

3.2.3.4 Prevention

3.2.3.5 Management

3.2.3.6 Prognosis

4 Industry Overview

4.1 Players in a Dynamic Market

4.1.1 Academic Research Lab

4.1.2 Diagnostic Test Developer

4.1.3 Instrumentation Supplier

4.1.4 Chemical/Reagent Supplier

4.1.5 Pathology Supplier

4.1.6 Independent Clinical Laboratory

4.1.7 Public National/regional Laboratory

4.1.8 Hospital Laboratory

4.1.9 Physicians Office Lab (POLS)

4.1.10 Audit Body

4.1.11 Certification Body

4.2 The Clinical Laboratory Market Segments

4.2.1 Traditional Market Segmentation

4.2.2 Laboratory Focus and Segmentation

4.2.3 Segmenting the Syndromic Testing Market

4.3 Industry Structure

4.3.1 Hospital Testing Share

4.3.2 Economies of Scale

4.3.3 Hospital vs. Central Lab

4.3.4 Physician Office Lab's

4.3.5 Physician's and POCT

5 Market Trends

5.1 Factors Driving Growth

5.1.1 The Nucleic Acid Impact

5.1.2 Population Dynamics

5.1.3 The Developing World

5.1.4 Decentralization

5.1.5 Self Testing

5.1.6 The Need for Speed

5.2 Factors Limiting Growth

5.2.1 Costs and Experience Curve Effects

5.2.2 The Role of ID Prevalence

5.2.3 Wellness

5.2.4 The Impact of Living Standards

5.3 Instrumentation, Automation and Diagnostic Trends

5.3.1 Traditional Automation and Centralization

5.3.2 The New Automation, Decentralization and Point of Care

5.3.3 Instruments Key to Market Share

5.3.4 Bioinformatics Plays a Role

5.3.5 PCR Takes Command

5.3.6 Next Generation Sequencing Fuels a Revolution

5.3.7 NGS Impact on Pricing

5.3.8 Whole Genome Sequencing, A Brave New World

5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

6.1 Recent Developments - Importance and How to Use This Section

6.1.1 Importance of These Developments

6.1.2 How to Use This Section

6.2 Presymptom Health Nabs Funding for Sepsis Test

6.3 FDA Clears BioMerieux GI Panel

6.4 Rapid Infection Diagnostic Launches BSIDx

6.5 Biotia's AI-, Sequencing-Based UTI Test approved

6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic

6.7 Roche Respiratory Panel Receives FDA EUA

6.8 Genetic Signatures Gets Approval for GI Parasite Panel

6.9 Diasorin Expands Respiratory Panel

6.10 BioMerieux Outlines MDx-Driven Growth

6.11 T2 Biosystems Gets Extended T2Bacteria Panel

6.12 Diasorin Aims to Deliver Updated Instruments, New Assays

6.13 Oxford Nanopore Nabs Investment From BioMerieux

6.14 Day Zero Diagnostics Closes Financing Round

6.15 Spindiag Seeks Investors for Rapid PCR System

6.16 Sorrento Therapeutics Nabs Contract for Dx Platform

6.17 Kephera Planning Menu of Infectious Disease Tests

6.18 Oxford Nanopore and BioMerieux to Develop IDDx

6.19 SD Biosensor Eyes Global Expansion

6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance

6.21 Takara Developing High-Throughput Multiplex Panels

6.22 BioGX Debuts New Point-of-Care Molecular Testing System

6.23 Nanopath MDx Platform Providing 15-Minute Results

6.24 ProtonDx Commercializing Rapid MDx Instrument

6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays

6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS

6.27 Accelerate Diagnostics Anticipates Growth

6.28 Lumos Diagnostics Expanding Test Portfolio

6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

7 Key Companies

7.1 Abbott Laboratories

7.2 Agilent

7.3 Altona Diagnostics

7.4 Anitoa

7.5 Autonomous Medical Devices

7.6 Beckman Coulter Diagnostics (Danaher)

7.7 Becton, Dickinson and Company

7.8 BioGX

7.9 Biomatik

7.10 bioMerieux Diagnostics

7.11 Bio-Rad Laboratories, Inc.

7.12 Cepheid (Danaher)

7.13 Diasorin S.p.A.

7.14 DNAe

7.15 Flow Health

7.16 Global Access Diagnostics

7.17 Great Basin Scientific, Inc.

7.18 Hologic

7.19 Novacyt

7.20 Novus Diagnostics

7.21 Oncimmune

7.22 One Codex

7.23 OraSure Technologies

7.24 Prometheus Laboratories

7.25 Qiagen

7.26 QuidelOrtho

7.27 R-Biopharm AG

7.28 Response Biomedical

7.29 Revvity

7.30 Roche Diagnostics

7.31 Siemens Healthineers

7.32 Thermo Fisher Scientific

7.33 Vela Diagnostics

7.34 Veredus Laboratories

7.35 YD Diagnostics

7.36 Zhejiang Orient Gene Biotech

8 The Global Market for Clinical Laboratory MDx Infectious Disease

8.1 Global Market Overview by Country

8.1.1 Table - Global Market by Country

8.1.2 Chart - Global Market by Country

8.2 Global Market by Application - Overview

8.2.1 Table - Global Market by Application

8.2.2 Chart - Global Market by Application - Base/Final Year Comparison

8.2.3 Chart - Global Market by Application - Base Year

8.2.4 Chart - Global Market by Application - End Year

8.2.5 Chart - Global Market by Application - Share by Year

8.2.6 Chart - Global Market by Application - Segments Growth

8.3 Global Market by Place - Overview

8.3.1 Table - Global Market by Place

8.3.2 Chart - Global Market by Place - Base/Final Year Comparison

8.3.3 Chart - Global Market by Place - Base Year

8.3.4 Chart - Global Market by Place - End Year

8.3.5 Chart - Global Market by Place - Share by Year

8.3.6 Chart - Global Market by Place - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

9.1 Respiratory

9.1.1 Table Respiratory - by Country

9.1.2 Chart - Respiratory Growth

9.2 Blood Borne Virus

9.2.1 Table Blood Borne Virus - by Country

9.2.2 Chart - Blood Borne Virus Growth

9.3 Transplant

9.3.1 Table Transplant - by Country

9.3.2 Chart - Transplant Growth

9.4 Hospital Acquired Infections

9.4.1 Table Hospital Acquired Infections - by Country

9.4.2 Chart - Hospital Acquired Infections Growth

9.5 Reproductive Health

9.5.1 Table Reproductive Health - by Country

9.5.2 Chart - Reproductive Health Growth

9.6 C19 Singleplex

9.6.1 Table C19 Singleplex - by Country

9.6.2 Chart - C19 Singleplex Growth

9.7 Meningitis

9.7.1 Table Meningitis - by Country

9.7.2 Chart - Meningitis Growth

9.8 Gastrointestinal

9.8.1 Table Gastrointestinal - by Country

9.8.2 Chart - Gastrointestinal Growth

9.9 Tropical

9.9.1 Table Tropical - by Country

9.9.2 Chart - Tropical Growth

10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place

10.1 Hospital Lab

10.1.1 Table Hospital Lab - by Country

10.1.2 Chart - Hospital Lab Growth

10.2 Outpatient Lab

10.2.1 Table Outpatient Lab - by Country

10.2.2 Chart - Outpatient Lab Growth

10.3 Point of Care

10.3.1 Table Point of Care - by Country

10.3.2 Chart - Point of Care Growth

10.4 Other Place

10.4.1 Table Other Place - by Country

10.4.2 Chart - Other Place Growth

11 Appendices

11.1 Growth of Approved IVD Test Menu

11.2 Growth of Approved Average IVD Test Fee

11.3 The Most Used IVD Assays

11.4 The Highest Grossing Assays

11.5 Laboratory Fees Schedule

List of Tables [32]

List of Figures [40]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/hf7tcb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.